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Sinary A novel quantitative ruminometric immunoassay (LIA) has been developed for the measurement of
wild-type and mutant p53 protein in extracts from breast tumour tissue. The LIA was found to yield reliable
estimates of p53 expression in cytosol samples routinely prepared for steroid receptor analysis as compared
with results obtained with immunohistochemical analysis. The LIA was evaluated on 205 primary breast
tumour cytosols prepared for steroid receptor analysis and stored frozen at -80'C for 6-8 years, p53 protein
being detected in 65% of the samples (range 0.01-23 ng mg'- protein). Using an arbitrary cut-off value of
0.15 ng mg-' protein, 30% of the tumours were classified as manifesting p53 overexpression. Significant and
independent correlations were found to exist between p53 overexpression and shorter disease-free (P<0.001)
and overall survival (P = 0.039) at a median duration of follow-up of 50 months. p53 overexpression was
related to low oestrogen receptor content and high proliferation rate (S-phase fraction). No relationship was
found to tumour size or the presence of lymph node metastasis. Three tumours possessed an extremely high
p53 content (> 10 ng mg- I protein), all of which were of medullary or high-grade ductal type, oestrogen and
progesterone receptor negative, DNA non-diploid, had S-phase fractions of >22% and recurred within 1-2
years. In summary, a new sensitive and quantitative LIA suitable for routine analysis of p53 protein in steroid
receptor cytosol preparations from breast tumours has been developed to confirm the prognostic importance
of p53 protein accumulation in human breast cancer.
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Alteration of the p53 tumour-suppressor gene or of its bio-
logical function as a cell cycle checkpoint is a frequent
feature of human cancer, and may represent the rate-limiting
step in the development of many tumours of all cell lineages.
This alteration is usually caused by missense point mutations
in the conserved regions of the gene and domains of the
protein important for function or structure (Hollstein et al.,
1991). Mutant p53 protein usually undergoes conformational
changes that prolong its normally very short half-life, result-
ing in its accumulation in the cell (Levine et al., 1991). This
has provided a convenient means of analysis using immuno-
chemical techniques on clinical specmens, expression at
detectable levels being taken as a rough measure of the
presence of gene mutations. Compatible with the theory that
p53 alterations predispose the cell to further genetic changes,
p53 overexpression seems to be an early event in some breast
tumours and to be present in non-invasive intraductal lesions
(Davidoff et al., 1991). In invasive breast cancer, p53 over-
expression has been associated with aggressive tumour
phenotype and shorter recurrence-free and overall survival,
thus constituting a possible independent prognostic marker
(Cattoretti et al., 1988; Isola et al., 1992; Thor et al., 1992;
Allred et al., 1993; Barnes et al., 1993).
To be clinically useful, prognostic markers should be acces-
sible to analysis with simple and reproducible procedures
appropriate for routine use with available tumour specimens.
So far, p53 overexpression has been analysed mainly with
immunohistochemical (IHC) techniques on frozen or fixed
tumour material. Although conveniently performed on archi-
val pathological material, the IHC technique suffers from
variations in tissue fixation conditions, a lack of reproducible
interpretation of staining intensity and cellularity, as well as
being restricted to histopathology laboratories. Here we des-
cribe a luminometric immunoassay (LIA) procedure for
quantitative analysis of mutant and wild-type p53 protein in
tumour extracts, and evaluate its applicability to the analysis
of breast cancer cytosol preparations routinely used in many
clinical laboratories for steroid receptor analysis. Using the
LIA test we confirmed the existence of correlation between
p53 overexpression and aggressive breast tumour phenotype
and poor prognosis.
MateraL and mwtbod
Patients
The 205 patients included in the retrospective part of the
study all came from the southern health care region of
Sweden, and were treated for primary breast cancer accord-
ing to the guidelines of the South Sweden Breast Cancer
Group. These patients were diagnosed as having primary
breast cancer without clinical evidence of generalised disease,
and were staged according to pathological examination of
tumour size and lymph node involvement. The duration of
follow-up was computed from the date of primary operation
to the date of an event (local or distant recurrence or death)
or to the date of the most recent follow-up, and was analysed
in terms of disease-free survival (DFS) and overall survival
(OS), median follow-up for patients still alive being 50
months. Most (73%) of the patients were given adjuvant
tamoxifen therapy for 2-5 years.
The 74 patients from whom primary breast tumour tissue
was used in the comparison of the p53 LIA test and IHC all
belonged to the south-east Sweden health care region.
Tunour tissuepreparation
A representative tumour section was cut out during patho-
logical examination and sent frozen for routine steroid hor-
mone receptor analysis. Tumour tissue was homogenised in a
microdismembrator (Braun, Melsungen, Germany) and sus-
pended in standard receptor buffer (10 mM Tris pH 7.4,
1.5 mM EDTA, 10 mm sodium molybdate, 1.0 mM monothio-
glycerol). Supernatants were colected after centrifugation at
20 000 g for Omin and used for steroid receptor analysis,
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residual supernatant being kept at - 80°C for subsequent
retrospective studies.
Lwninometric immunoassay
A sandwich-type luminometnic immunoassay (LIA) proce-
dure was developed for quantitative measuring of both
mutant and wild-type p53 protein in tumour tissue. The LIA
uses two monoclonal antibodies for denaturation-resistant
epitopes (different sites) at the N-terminus of the p53 protein:
polystyrene tubes coated with PAb 1801 monoclonal anti-p53
antibody (Banks et al., 1986) and a tracer solution consisting
of an aminobutylethylisoluminol (ABEI)-conjugated DOI
monoclonal antibody (Vojtesek et al., 1992).
Preparation ofantibody coated tubes Polystyrene tubes were
incubated overnight at room temperature with 3 Ag of PAb
1801 in 200 IL of Tris-HCI pH 8.5. The tubes were washed
with 0.1% Tween in phosphate-buffered saline (PBS), treated
with 300 jIl of 0.3% bovine serum albumin (BSA), and after
repeated washing dried overnight at room temperature.
Preparation of the LIA tracer ABEI (Sigma) was linked
with a diactivated ester (Byk-Sangtec, Diagnostica, Dietzen-
bach). This ABEI conjugate was mixed with DOI antibody
(1 mgmrl', in an approximately 40:1 molar ratio) in 50-
100 II of PBS, pH 7.4, containing 15% acetonitrile, and
incubated for 1 h at room temperature. The ABEI-conjugat-
ed antibody was purified on a Sephacryl S 300 HR (Phar-
macia) gel filtration column, and appropriate fractions were
pooled and diluted in buffer containing 25 mM Tris-HCI,
pH 7.5, 0.05% sodium azide, 0.005% Tartazin XX85, 0.15%
Triton X-100, 37.5 mM sodium chloride and 0.5% bovine
serum albumin (BSA).
Test procedure The LIA is conducted in a single incubation
step by adding 100 tlI of tracer and 100IlI of cytosol or p53
standard (in diluent buffer: 20 mM Tris-HCI pH 7.5, 0.5 mM
EDTA, 15 mM sodium chloride, 0.5% Triton-X 100, 1%
BSA, 0.5 mg ml-' polyethylene glycol 6000, 0.05% sodium
azide) to the antibody-coated tubes. After incubation over-
night at room temperature, the tubes were washed four times
with 2 ml of 0.15 M sodium chloride. The luminescence was
determined using the LIA-mat starter service kit (Byk-Sang-
tec) and immediately measured as integrals over a period of
5 s in a 952 Berthold luminometer. The assay was standar-
dised using pure soluble recombinant wild-type human p53
protein isolated from bacteria (Midgley et al., 1992). The p53
protein concentration was determined with amino acid
analysis. The standard curve (Figure 1) was calculated with a
curve-fitting programme (spline smooth Multicaic, Wallace
OY, Turku Finland), the p53 content (ng ml-') being deter-
mined per RLU (relative light unit). The detection limit (zero
standard + 3 standard deviations) was approximated to be
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Figwe I The p53 LIA standard curve, using known amounts of
recombinant human p53 protein.
0.01 ng ml-'. The concentration of p53 protein was expressed
in ng mg- lcytosol protein, the cytosol protein concentration
being in the range 0.5-4.0mgml-'.
Immunohistochemistry
Sections (6 ;tm thick) of frozen tumour tissue were stained
with monoclonal antibodies PAb 1801 (Banks et al., 1986)
and DOI (Vojtesek et al., 1992), using the peroxidase-con-
jugated streptavidin-biotin technique. IgG antibodies were
used as negative control (Sigma, St Louis, MO, USA). The
tumours were collected from fresh surgical resections and
stored below - 70'C before being cut, air dried and stored at
-20'C for IHC. The sections were then fixed in acetone
(4'C) for 10 min and air dried. Endogenous peroxidase
activity was quenched with 0.6% hydrogen peroxide in
methanol for S min, whereafter the slides were rinsed with
PBS containing 0.1% BSA and 0.5% Tween (PBS-BSA-
Tween). To block endogenous avidin-binding activity, the
tissue was first treated with avidin (0.001%) and then, after
rinsing with PBS-BSA-Tween, with 0.01% biotin (Sigma).
The sections were rinsed and placed in PBS-BSA-Tween for
5 min. Normal goat serum (1:5) was used for 20 min in order
to block non-specific immunostaining. The sections were
incubated with the pimary antibodies PAb 1801 (1:100) or
DOI (1:100) for 30min, then with biotinylated goat anti-
body (1:500) for 30min, and, after being rinsed with PBS-
BSA-Tween, incubated with streptABComplex/horseradish
peroxidase (1:500; Dako A/S, Glostrup, Denmark) for
30 min. The sections were rinsed with PBS-BSA-Tween
before they were stained with 3,3-diaminobenzidine tetra-
hydrochloride (DAB) in PBS containing 0.036% hydrogen
peroxide for 8 min, then rinsed with distilled water, counter-
stained with haematoxylin, stepwise dehydrated in ethanol,
cleared in xylene and mounted.
Staining was evaluated by rating the proportion of stained
cancer cells (0%, 1-10%, 10-50% or > 50%), samples
being classified as negative (-) or weakly (+), moderately
(+ +) or strongly positive (+ + +) respectively.
Steroid receptor analysis
Steroid receptor content was determined with radioligand
techniques [isoelectric focusing for oestrogen receptor (ER)
content, and the dextran-coated charcoal assay with Scat-
chard analysis for progesterone receptor (PgR) content], per-
formed on 20 000 g supernatants of tumour homogenate, as
previously described (Norgren et al., 1982), using the Lowry
assay for total cytosol protein determination. A cut-off level
of 10 fmol mg-' protein was used to classify tumours as
receptor positive or negative.
DNAflow cytometry
The DNA content in individual cell nuclei was analysed with
flow cytometry (Ortho cytofluorograph 50-H system) after
staining with propidium iodide (Baldetorp et al., 1989). DNA
ploidy status was classified as diploid (one stem cell popula-
tion) or non-diploid (two or more stem cell populations). The
percentage of nuclei corresponding to the S-phase fraction
(SPF) was calculated planimetrically, cut-off levels of 7.0%
and 12.0% being adopted to allow classification of tumours
according to three categories: low, intermediate and high
SPF (Sigurdsson et al., 1990).
Statistical analysis
The rates of p53 overexpression in different tumour or
patient subgroups were compared with Spearman's rankl cor-
relation and Pearson's chi-square analysis. Life-table analyses
of differences between survival data were performed with the
Cox's proportional hazards model.
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Comparison ofthe LIA test with imunohistochemical staining
IHC is the technique most commonly used for measurement
of p53 expression. Evaluation of new assays such as the LIA
test should be done by comparison with IHC Hence, the
results from LIA analysis of p53 protein content in freshly
prepared cytosol samples from 74 primary breast tumours
were compared with IHC staining of frozen sections from the
same tumour tissues. IHC was performed using both of the
two monoclonal antibodies from the LIA (PAb 1801 and
DOI) in separate experiments. The results from this compari-
son are presented in Figure 2. A higly significant correlation
(r, = 0.55, P<0.0001) was found between the quantitative
LIA test and the semiquantitative IHC staining (using the
PAb 1801 antibody), only one case displaying a considerable
diverging pattern in being strongly positive by IHC but
manifesting relatively low expression (0.15 ngmg-1) by LIA.
A similarly strong correlation was seen between the two
techniques when using the DOl antibody in IHC.
Clinical evaluation ofthep53 LIA test in tumour cytosols
The LIA test was evaluated on 205 breast cancer cytosols
(20 000 g supernatants) stored frozen at -80C for 5-8
years. p53 protein expression was found in 133 (65%) of the
cytosols (range 0.01-23ngmg-' protein; median, 0.053ng
mg-' protein). The p53 concentration was low (<O.1Ong
mg-' protein) in 126 (61%), intermediate (0.10-1.0 ngmg-')
in 59 (29%), and high (>l.Ongmg-') in 20 (10%) of the
cytosols, three of which had extremely high values (12, 22
and 23 ngmg-' protein). In general, there was a sinf tly
lower level ofp53 content in these stored cytosols (which had
been frozen and thawed twice in the process of analysis) as
compared with the freshly prepared cytosols from the com-
parison with IHC analysis, the percentage of samples with a
c
0
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0
0
0
p53 content > 0.10 ng mg' protein being 39% and 74%
respectively.
To evaluate the relationship between p53 expression and
tumour behaviour, different cut-off values were tested for
their ability to identify a subgroup of patients with p53
overexpression and poor prognosis. Although several levels
of expression yielded prognostic information, a cut-off value
of 0.15 ng mg-' protein was found to yield the best discrim-
ination of patients with good vs poor prognosis (Figure 3).
Using the optimised cut-off value in univariate survival
analysis, a subgroup of 62 patients (30%) whose tumours
manifested p53 overexpression was identified as having a
significantly shorter DFS (P = 0.003) in univariate survival
analysis than patients whose tumours manifested low or no
p53 expression (Table I). The relationship to an OS did not
reach statistical signifince (P = 0.10).
In multivariate survival analysis of all 205 patients, includ-
ing standard prognostic factors as covariates, p53 overex-
pression was found to be an independent predictor of both
DFS (P<0.001) and of OS (P = 0.039; Table I).
Using the same cut-off level (0.15 ngmg-' protein), p53
overexpression was found to be related (non-significantly) to
ER negativity and high S-phase fraction values (Table HI).
Overexpression of p53 was not related to lymph node status,
tumour size, PgR status, DNA non-diploidy or patient age/
menopausal status.
The three tumours possessing an extremely high level of
p53 protein expression were characterised by an exceptionally
aggressive phenotype and clinical course. All were of medul-
lary or high-grade ductal histological type, ER and PgR
negative, DNA non-diploid, and had very high SPF values
(> 22%). All three patients developed early distant recur-
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Fue 2 p53 expression values (logarithms) obtained by LIA in
74 primary breast tumour cytosols as compared with immunohis-
tochemical p53 staining (using the PAb 1801 monoclonal anti-
body), scored as negative (-), weakly (+), moderately (+ +)
and strongly positive (+ + +).
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Fgwe 3 Determination of optimal cut-off levels of p53 expres-
sion, obtained by LIA, for predicting disease-free survival in 205
cases of breast cancer. P-values obatined for each cut-off level are
plotted against the value itself. Statistical signifianc is indicated
by the horizontal line at the 0.05 level. Optimal cut-off level is
indicated by an arrow.
Table I Disease free (DFS) and overall sunrival (OS) in 205 primary breast cancer cases, as determined
with univariate and multivariate analysis
DFS OS
P-value RR P-value RR
Variable Univariate Multivariate (95% CI) Univariate Multivariate (95% CI)
Lymph nodes
1-3 NS NS NS NS
)4 <0.001 <0.001 41. (2.1-8.0) <0.001 <0.001 3.6 (1.9-6.7)
Tumour size NS NS NS NS
Menopause 0.044 0.009 2.2 (1.2-4.1) NS NS
ER 0.044 NS 0.005 NS
PgR <0.001 0.004 2.6 (1.3-5.0) <0.001 0.002 2.6 (1.4-4.7)
p53 0.003 <0.001 2.7 (1.6-4.6) NS 0.039 1.8 (1.0-3.0)
The multivariate analyses were performed with Cox's proportional hazards model, the variables entered
stepwise. P-values and relative risks (RR) with 95% confidence intervals (Cl) are presented only for
significant and retained vanables. Vanables were categorized as: lymph node status (O vs 1-3 vs 4
positive nodes); tumour size ( 20 mm vs >20 mm); menopausal status (post vs pre); oestrogen receptor
status (ER 10 vs <10 fmolmg ' protein); progesterone receptor status (PgR 10 vs <l0fmnolnml'
protein); p53 (<0.15 vs ) 0.15 ng mg' protein). NS, not significant (>0.05).
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rence and died of their diseas (Table H). On the other
hand, of 24 patients manifesting a sfimilarly aggrssive
tumour phenotype (ER and PgR negative, DNA non-diploid,
high SPF) but low or no p53 expression, only eight
developed recurrence and died of their disease.
Two of the three tumours with very high p53 content
manifested evidence of p53 gene mutations (in exons 5 and 8
respectively) by constant denaturing gel electrophoresis ana-
lysis, while in the third tumour no alterations were found in
exons 5-8 (data not shown).
One of the primary objectives in breast cancer research is the
identification of new bioloical markers of tumour behaviour
for better prediction of recure and survival (McGuimre,
1991). Promising in this respect are the p53 gene and the
alterations which result in loss of its cel cycle checkpoint
function, as these changes may represent a stage in which the
acquisition of further genetic alterations of importance in
tumour progression is promoted (Lane, 1992). Of equal
importance is to obtain a better understanding of the mech-
anisms behind treatment failure. Again, loss of the p53-
mediated process of programmed cell death in resonse to
DNA-damaging drugs or radiation is a plausible explanation
for resistance to these types of therapy (Lane, 1993).
The p53 gene is usually altered by point mutations result-
ing in amino acid substitutions and conformational changes
in the protein, which, owing to increased stability and pro-
longed half-life, accumulates in the cell to readily detectable
Tabk H Relationship between p53 protein overexpron and
other prognostic factors in 205 primary breast tumours
No. of p53 overexpression
Variable/category thnours (%) P-value
All 205 30 -
Menopausal status
Pre 69 29
Post 136 31 0.78
Lymph node status
Negative 85 36
1-3 positive 75 25
4+ positive 44 27 0.27
Tumour size (mm)
<20 81 28
>20 124 31 0.64
Oestrogen rmeptors (fmol)
<10 70 39
.10 135 26 0.062
Progesterone receptors (fmol)
<10 91 33
.10 114 28 0.45
DNA ploidy
Diploid 50 28
Non-diploid 97 33 0.54
S phase fraction (%)
<7.0 53 23
7.0-12 24 42
.12 62 39 0.12
aPearson x2 test
levels. Findings from several retrospective studies support the
putative correlation between p53 overexpression, as assessed
by IHC, and aggressive tumour phenotype, and emphasise its
chnical usefulness as an independent prognostic factor (Catto-
retti et al., 1988; Thor et al., 1992; Isola et al., 1992; Allred et
al., 1993; Barnes et al., 1993; Thor and Yandell, 1993).
In the present study, we used a novel and simple LIA for
the measurement ofp53 protein which fulfils the demands of
a clinical assay in being sensitive, quantitative and appro-
priate for the routine analysis ofavailable tumour specmems.
The p53 LIA test was evaluated on breast cancer cytosol
samples prepared for the analysis of steroid receptors and
routinely asd in many laboratories for predicting the
efficacy ofhormonal (tamoxifen) therapy of recurnt disease
or in the adjuvant setting. As with a similar enzyme-linked
immunosorbent assay technique recently described (Vojtesek
et al., 1993), the LIA test was found to yield estimates ofp53
expression similar to those obtained with IHC, with the
advantage of being quantitatively objective, reproducible and
simple to perform on residual biopsy material.
The importance of a quantitative measurement of p53
expression was shown in previous IHC studies, in which a
subgroup of 10-20% manifestly p53-positive (strong staining
intensity and/or high proportion of stained cells) tumours
was found to be associated with worse prognosis than
tumours that were weakly p53 positive or p53 negative (Isola
et al., 1992; Thor et al., 1992; Allred et al., 1993; Banes et
al., 1993). These findings derived further support from those
of the present study, in which a cut-off level at 0.15 ng p53
per mg of protein identified a subgroup of 30% of the
tumours, a category charactenised by significant and indepen-
dent correlation with poor disease-free and overall survival.
Although the results are promising, the relatively small
number of patients with heterogeneous disease (both node-
negative and node-positive, different adjuvant therapy) used
in the present study necessitates further evaluation of the
LIA in better-defined patient groups. Moreover, the arbi-
trarily chosen cut-off point should be critially interpreted
and not directly applied in other studies as the condition
(freezer storage) of the cytosol sampes may affect antigen
recovery.
In agreement with previous studies (Cattoretti et al., 1988;
Isola et al., 1992; Thor et al., 1992; Allred et al., 1993;
Banes et al., 1993), p53 overexpression was related to oes-
trogen receptor negativity, and was also associated with a
high proliferation rate expressed as the percentage of cells in
the S-phase fraction (SPF). This relationship was particularly
evident in tumours with a very high level of p53 expression,
tumours which were found to be of medullary or high-grade
ductal type, confirming previous findings of a correlation
between p53 overexpression and histological type (Domagala
et al., 1993). The fact that p53 mutations could be detd
(by screening the conserved regions of the gene) in only two
of the three tumours manifesting an extremely high p53
content suggests the existence of altemative mechanisms
behind this accumulation.
The p53 LIA assay, using two highly specific and sensitive
monoclonal antibodie for wild-type and mutant p53 protein,
should be useful for the analysis of p53 protein in breast
tumour cytosols, as well as in other tumour extracts and
body fluids. The assay could easily be adapted for routine
clinical use in conjunction with the analysis of steroid recep-
tors in breast cancer, and may be of value in seleting
patients for more intensive follow-up or adjuvant therapy.
Table m Tumour and patient characteristics of three cases with extremely high cytosol p53 protein content
Tunour Patient
Patient p53 (ngmg'Histology Size Nodes ER PgR DNA SPF Age Recovered Dead
no protein) type (mm) N pos (finolmg-'protein) dx (%) (years) (months) (months)
4635 22 M dullary 26 0 0 0 1.71 26 41 13 20
5811 12 Ductal 45 1 0 0 1.87 22 50 25 54
5970 23 Medullary 35 4 0 0 1.68 24 70 17 22
'Ductal cancer with high nuclear grade.
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